Glox Therapeutics creates precision antibiotics through the use of engineered protein bacteriocins.
Glox Therapeutics has raised $617K in total funding. The most recent round was Grant. The last funding was announced in January 2025.
Glox Therapeutics's investors include Boehringer Ingelheim Venture Fund, Scottish Enterprise, PACE-AMR, CF AMR Syndicate.
Glox Therapeutics is headquartered in Glasgow, United Kingdom.
Glox Therapeutics creates precision antibiotics through the use of engineered protein bacteriocins.
Glox Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Glox Therapeutics — Funding & Investors." VCBacked, January 21, 2025, https://www.vcbacked.co/company/glox-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). Glox Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/glox-therapeutics
{{cite web |title=Glox Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/glox-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated